Novel Treatments - Research Article

Ranjan E.a· Arora S.b· Sharma A.S.c· Sharma N.d· Dabas R.e

Author affiliations

aDepartment of Dermatology, Military Hospital, Jammu, India
bDepartment of Dermatology, Base Hospital, Delhi, India
cDepartment of Pathology, Military Hospital, Jammu, India
dDepartment of Public Health, PGIMER, Chandigarh, India
eDepartment of Dermatology Command Hospital, Udhampur, India

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Received: July 30, 2022
Accepted: September 22, 2022
Published online: April 14, 2023

Number of Print Pages: 7
Number of Figures: 5
Number of Tables: 3

ISSN: 2296-9195 (Print)
eISSN: 2296-9160 (Online)

For additional information: https://www.karger.com/SAD

Abstract

Introduction: Onychomycosis is a common nail disorders. Antifungal resistance, interactions, and side effects limit treatment options. Fractional CO2 (FCO2) laser along with topical antifungal is effective in multiple monthly sessions. A modification reducing repeated visits and hence better compliance is preferable. Single-session FCO2 laser following urea occlusion is reported to be effective. Thus, we conducted a study to determine the efficacy of single-session FCO2 laser with 1% terbinafine cream with and without “urea cream occlusion” in managing onychomycosis. Methods: A prospective, randomized, parallel-group study was conducted at a tertiary centre. Onychomycosis was confirmed by positive fungal mount and culture. Patients were randomized into 2 groups and administered single-session FCO2 laser. Group A was treated after overnight urea cream occlusion and group B without occlusion. Both groups applied 1% terbinafine cream twice daily for 3 months. Response was assessed by improvement in Onychomycosis Severity Index (OSI) at 6 months. Results: Group A had 10 patients, 14 nails. Clinical improvement was seen in 12/14 (85.7%) nails. Average reduction in OSI was 10.78. Group B had 10 patients, 11 nails. Clinical improvement was seen in 5/11 (45.5%) nails. Average reduction in OSI was 1.73. “Reduction in OSI” was statistically significant (p < 0.05) only in group A. Conclusion: Single-session FCO2 laser following overnight urea cream occlusion, followed by 1% terbinafine cream, is effective for management of onychomycosis.

© 2023 S. Karger AG, Basel

References Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population: a literature study. J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1480–91. Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M, Faergemann J, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol. 2007 Jul;157(1):149–57. Lipner SR, Scher RK. Onychomycosis: treatment and prevention of recurrence. J Am Acad Dermatol. 2019 Apr;80(4):853–67. Kandpal R, Arora S, Arora D. A study of Q-switched Nd:YAG laser versus itraconazole in management of onychomycosis. J Cutan Aesthet Surg. 2021 Mar;14(1):93–100. Demirseren DD. New therapeutic options in the management of superficial fungal diseases. Dermatol Ther. 2020 Nov;33(6):e12855. Lim E-H, Kim HR, Park Y-O, Lee Y, Seo Y-J, Kim C-D, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol. 2014 May;70(5):918–23. Arora S, Lal S, Janney MS, Ranjan E, Donaparthi N, Dabas R. Fractional CO2 laser in the management of onychomycosis. J Mar Med Soc. [cited 2022 Feb 4]. Available from: https://www.marinemedicalsociety.in/article.asp?issn=0975-3605;year=2020;volume=22;issue=1;spage=50;epage=53;aulast=Arora. Zhou BR, Lu Y, Permatasari F, Huang H, Li J, Liu J, et al. The efficacy of fractional carbon dioxide (CO2) laser combined with luliconazole 1% cream for the treatment of onychomycosis: a randomized, controlled trial. Medicine. 2016 Nov;95(44):e5141. Bhatta AK, Keyal U, Huang X, Zhao JJ. Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis. J Am Acad Dermatol. 2016 May;74(5):916–23. Shi J, Li J, Huang H, Permatasari F, Liu J, Xu Y, et al. The efficacy of fractional carbon dioxide (CO2) laser combined with terbinafine hydrochloride 1% cream for the treatment of onychomycosis. J Cosmet Laser Ther. 2017 Oct;19(6):353–9. Ranjan E, Arora S, Sharma N. Fractional CO2 laser with topical 1% terbinafine cream versus oral itraconazole in the management of onychomycosis: a randomized controlled trial. Indian J Dermatol Venereol Leprol. 2023;89(1):47–53. Arora S, Ranjan E. Urea occlusion prior to single session fractional CO2laser as a treatment in onychomycosis. Indian J Dermatol Venereol Leprol. 2020 Jun;86(3):331–3. Kozarev J, Vizintin Z. Novel laser therapy in treatment of onychomycosis. J LAHA. 2010 Jan 1:1. Carney C, Tosti A, Daniel R, Scher R, Rich P, DeCoster J, et al. A new classification system for grading the severity of onychomycosis: onychomycosis severity Index. Arch Dermatol. 2011 Nov 1;147(11):1277–82. Article / Publication Details

Received: July 30, 2022
Accepted: September 22, 2022
Published online: April 14, 2023

Number of Print Pages: 7
Number of Figures: 5
Number of Tables: 3

ISSN: 2296-9195 (Print)
eISSN: 2296-9160 (Online)

For additional information: https://www.karger.com/SAD

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.